SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059995
Filing Date
2024-05-15
Accepted
2024-05-15 06:19:31
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q elym-20240331.htm   iXBRL 10-Q 1489845
2 EX-10.6 elym-ex10_6.htm EX-10.6 108063
3 EX-31.1 elym-ex31_1.htm EX-31.1 15692
4 EX-32.1 elym-ex32_1.htm EX-32.1 9507
  Complete submission text file 0000950170-24-059995.txt   6513076

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elym-20240331.xsd EX-101.SCH 1117113
63 EXTRACTED XBRL INSTANCE DOCUMENT elym-20240331_htm.xml XML 922591
Mailing Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808
Business Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

IRS No.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40708 | Film No.: 24946969
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)